Sonib 200 mg (Sorafenib Tosylate)

Sonib 200 mg (Sorafenib Tosylate) is an oral oncology formulation that has been used in clinical settings for managing certain advanced cancers such as liver, kidney, and thyroid malignancies. As a targeted therapy, it works by inhibiting tumor growth and angiogenesis in the cancer cells and helps further growth of tumor. 

It is manufactured by Drug International Ltd and can access this globally through Onus Pharma, a trusted supplier for oncology medication. 

Information here is for general awareness and not a substitute for professional medical advice.

What is Sonib 200 mg (Sorafenib Tosylate) used for?

Sonib 200 mg (Sorafenib Tosylate) may be prescribed for patients diagnosed with the following conditions. 

• Patients with Hepatocellular Carcinoma and can not go for other treatment.
  
• Patients with advanced kidney cancer which has been spread to the other parts of the body.
• It is also used to treat Differentiated thyroid carcinoma (DTC) patients with progressive, radioactive iodine-refractory thyroid cancer.

How does Sonib 200 mg tablet work in cancer treatment?

It is a multi kinase inhibitor, targets both tumor cell proliferation and angiogenesis, works by blocking intracellular and cell surface kinases that take part in tumor growth and blood vessel formation. This dual mechanism ability may be considered in patients who have not responded to standard therapy with those diseases. 

Side effects

Serious adverse reactions are cardiac ischemia, infarction, hemorrhage, hypertension, hand-foot skin reaction and rash, gastrointestinal perforation, wound healing complications.

Precautions

• Cardiac Ischemia and Infarction: Temporary or permanent discontinuation should be considered if patients develop cardiac ischemia or infarction.
  
• Risk of Hemorrhage: it may increase bleeding risk. In RCC studies, fatal hemorrhages occurred. If bleeding requires medical intervention, permanent discontinuation is advised.
• Risk of Hypertension: Hypertension occurred in about 9.4% of HCC and 16.9% of RCC patients treated with this drug. Severe or persistent hypertension despite treatment may require temporary or permanent discontinuation.
  
• Dermatologic Toxicities: Hand-foot skin reaction and rash are common adverse effects associated with this drug.
  
• Gastrointestinal perforation: consult with a licensed healthcare provider, they might tell you to stop taking the medicine if this happens.
• Warfarin Co-Administration: People who are taking warfarin should have regular checks of prothrombin time and INR as well as signs of bleeding.
• Wound Healing Problems: Starting this medication again after a major surgery should depend on clinical judgment about wound healing.
• Use with Carboplatin and Paclitaxel in NSCLC: Greater death rate in patients with squamous cell cancer getting Sonib 200 mg tablet plus carboplatin and paclitaxel than those getting only carboplatin and paclitaxel.
• Interactions with UGT1A1 Substrates: It could make plasma levels higher for drugs broken down by UGT1A1.
• Interaction with Docetaxel & Doxorubicin: It might increase the plasma amounts of Docetaxel and Doxorubicin.
• Hepatic Impairment: Liver disease might lower plasma levels of the drug.

Sonib 200 mg dosage instructions and administration guide

Typical dosing regimens may include twice-daily oral administration. Dosage should be determined by a qualified healthcare provider. Take this with water on an empty stomach, one hour before or two hours after eating. Continue the treatment with the doctor’s suggestion if clinical benefit is seen or other adverse effects are observed. Contact your doctor for dosage reduction and administration if necessary. 

Hand-Foot Skin Reaction (HFSR) Management:

• Grade 1 (mild): Continue Sonib 200 mg (Sorafenib Tosylate); use topical treatments if needed.
  
• Grade 2 (moderate): Continue treatment initially. If no improvement in 7 days or with repeated occurrence, pause therapy and resume at a reduced dose once symptoms improve.
  
• Grade 3 (severe): Interrupt therapy immediately. Resume at a lower dose once improved; discontinue after repeated severe episodes.
  

Missed Dose: Skip it and continue with the next scheduled dose. Do not double up.

Drug interactions

There are some drugs that may reduce the efficacy of Sonib 200 mg (Sorafenib Tosylate). Discuss with your physician if you are on any of the below-stated drugs since they may react with Sorafenib. 

• CYP3A4 Inducers(rifampin, phenytoin, carbamazepine) possibly reduced blood level.
•  CYP3A4 Inhibitors(ketoconazole, clarithromycin) possibly increased the level of sorafenib in the blood. 
• Warfarin and other anticoagulant drugs increased bleeding hazard.
• Some medications that prolong the QT interval, like amiodarone, might raise the chance of having heart rhythm problems.

• Dexamethasone and other corticosteroids possibly  may alter the metabolism of the medication.
• St. John’s Wort can lower the effectiveness of the blood.

 Contradictions

Sonib 200 mg (Sorafenib Tosylate) has potential contradiction with the following situation Hypersensitivity, Severe hepatic impairment, Pregnancy and breastfeeding, Uncontrolled hypertension, Severe cardiac conditions

Sonib Tablet uses in Special Population

Pediatric Use: There is a lack of information about the safety and effectiveness in the children. 

Geriatric Use: There might be a significant difference in effectiveness for young and older patients. 

Renal Impairment: No dosage adjustment is needed for patients with mild, moderate, or severe renal impairment.

Hepatic Impairment: In the population of patients having mild (Child-Pugh A) and moderate (Child-Pugh B) liver impairment, the drug exposure may be 23–65% less compared to those having normal liver function. However, systemic exposure in hepatocellular carcinoma patients with Child-Pugh A and B is the same as safety. Sonib 200 mg (Sorafenib Tosylate) has not been studied in patients having severe hepatic impairment, that is, in a population characterized as Child-Pugh C; hence, caution should be administered or avoided in this group.

Storage

Store The medication below 30°C in a dry place, away from sunlight and moisture. Keep it in the original bottle with the desiccant and cap tightly closed. Do not transfer to other containers. Keep out of reach of children, avoid storing in humid areas, and do not use after the expiry date. Proper storage ensures effectiveness and safety.

Sonib tablet price in Pakistan and Bangladesh – Updated 2025

It may cost about $90-$100 in Pakistan, India and other middle east countries. Price information may vary by region. For further details, consult a licensed distributor.

Frequently Asked Questions

Can I use this medication for a long time?

In clinical settings, it has been used long-term under supervision, provided an individual tolerates it well without much side effect. In most cases, monitoring by a doctor on the development of any adverse reactions and dosage adjustments will be required. Treatment duration is typically based on benefit-risk evaluation by the clinician. that outweigh the risks.

Is there any alternative brand available for Sonib 200 mg tablet?

 Alternatives are also other targeted therapies that may be related to the type of cancer such as Lenvatinib, Cabozantinib, and Regorafenib. The choice is made by your oncologist depending on your condition between responses and side effects.

How long does it take to work?

The effects of Sonib 200 mg (Sorafenib Tosylate) vary from patient to patient and cancer type being treated but it usually takes several weeks to months before any clinical benefit can be realized. Regular follow-up accompanied by imaging tests is used to assess response to treatment.

“This page is for informational purposes only. Please consult your healthcare provider for professional advice. This is not an advertisement or promotional claim.”